comments is available as described in Units I.B.1. and I.B.2.

IV. Policies Not Rules

The policy document discussed in this notice is intended to provide guidance to EPA personnel and decision-makers, and to the public. As a guidance document and not a rule, the policy in this guidance is not binding on either EPA or any outside parties. Although this guidance provides a starting point for EPA risk assessments, EPA will depart from its policy where the facts or circumstances warrant. In such cases, EPA will explain why a different course was taken. Similarly, outside parties remain free to assert that a policy is not appropriate for a specific pesticide or that the circumstances surrounding a specific risk assessment demonstrate that a policy should be abandoned.

List of Subjects

Environmental protection, Administrative practice and procedure, Agricultural commodities, Pesticides and pests.

Dated: June 15, 2000.

Susan H. Wavland,

Acting Assistant Administrator for Prevention, Pesticides and Toxic Substances. [FR Doc. 00–15917 Filed 6–22–00; 8:45 am]

BILLING CODE 6560-50-F

FEDERAL HOUSING FINANCE BOARD

Sunshine Act Meeting: Announcing an Open Meeting of the Board

TIME AND DATE: 10 a.m., Friday, June 23, 2000.

PLACE: Board Room, Second Floor, Federal Housing Finance Board, 1777 F Street, N.W., Washington, D.C. 20006.

STATUS: The entire meeting will be open to the public.

MATTERS TO BE CONSIDERED DURING PORTIONS OPEN TO THE PUBLIC:

- Final Rule: Amendments to Membership Regulation and Advances Regulation.
- Final Rule: Election of Federal Home Loan Bank Directors.
- Resolution Required by Section 608 of the Federal Home Loan Bank Modernization Act Certifying that Withdrawal of Bank System Members will not cause the Bank System to fail to meet its REFCorp Obligations.

CONTACT PERSON FOR MORE INFORMATION: Elaine L. Baker, Secretary to the Board, (202) 408–2837.

William W. Ginsberg,

Managing Director. [FR Doc. 00–16009 Filed 6–20–00; 4:59 pm]

FEDERAL HOUSING FINANCE BOARD

Sunshine Act Meeting: Announcing an Open Meeting of the Board

TIME AND DATE: 2 P.M., Thursday, June 29, 2000.

PLACE: Board Room, Second Floor, Federal Housing Finance Board 1777 F Street, N.W., Washington, D.C. 20006.

STATUS: The entire meeting will be open to the public.

MATTERS TO BE CONSIDERED DURING PORTIONS OPEN TO THE PUBLIC:

- Final Rule: Federal Home Loan Bank Acquired Member Assets, Core Mission Activities, Investments and Advances.
- Final Rule: Amendments to Advances and Other Regulations to Implement Gramm-Leach-Bliley Act Collateral Provisions and Make Related Revisions.

CONTACT PERSON FOR MORE INFORMATION: Elaine L. Baker, Secretary to the Board, (202) 408–2837.

William W. Ginsberg,

Managing Director. [FR Doc. 00–16010 Filed 6–20–00; 4:59 pm] BILLING CODE 6725–01–P

FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

Employee Thrift Advisory Council; Amended Meeting

FR.00–14739 appearing on page 36906 in the **Federal Register** of Monday, June 12, 2000, change the time of the meeting from 10 a.m. to 2 p.m. on Tuesday, June 27, 2000. Everything else remains the same.

Dated: June 20, 2000.

Elizabeth S. Woodruff,

General Counsel, Federal Retirement Thrift Investment Board.

[FR Doc. 00–15958 Filed 6–22–00; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Research Integrity Office Findings; Lingxun Duan, M.D.

AGENCY: Office of the Secretary, HHS. **ACTION:** Notice.

SUMMARY: Notice is hereby given that based on oversight by the Office of Research Integrity (ORI) and decision by the Assistant Secretary for Health, the U.S. Public Health Service has taken final action in the following case:

Lingxun Duan, M.D., Thomas Jefferson University: The U.S. Public Health Service (PHS) alleges that Dr. Duan, former Research Assistant Professor of Medicine, Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, engaged in scientific misconduct by reporting research that was inconsistent with original data or could not be supported because original data were not retained. The research in question was supported by a National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), grant, R01 AI36552, entitled "Intracellular antibodies and HIV 1.'

Specifically, the research in question was reported in an NIAID, NIH, grant application; in an FDA-approved phase I gene therapy investigational new drug (IND) application entitled "Intracellular immunization against HIV—1 infection using an anti-rev single chain variable fragment (SFV);" and in two publications: (1) Duan, L., Bagasra, O., Laughlin, M.A., Oakes, J.W., & Pomerantz, R.J., "Potent inhibition of human immunodeficiency virus type I replication by an intracellular anti-Rev single chain antibody," Proc. Natl. Acad. Sci. USA 91:5075-5079, 1994; and (2) Levy-Mintz, P., Duan, L., Zhang, H., Hu, B., Dornadula, G., Zhu, M., Kulkosky, J., Bizub-Bender, D., Skalka, A.M., and Pomerantz, R.J., "Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase," J. Virol. 70:8821-8823, 1996.

Dr. Duan denies all allegations of scientific misconduct and contends that some of his original data is missing. Both Dr. Duan and PHS are desirous of concluding this matter without further expense of time and other resources. Thus, Dr. Duan has entered into a Voluntary Exclusion Agreement (Agreement) with PHS, in which Dr. Duan has voluntarily agreed: